203 related articles for article (PubMed ID: 20086108)
1. Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma.
Poole EM; Hsu L; Xiao L; Kulmacz RJ; Carlson CS; Rabinovitch PS; Makar KW; Potter JD; Ulrich CM
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):547-57. PubMed ID: 20086108
[TBL] [Abstract][Full Text] [Related]
2. Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Kulmacz RJ; Potter JD; Ulrich CM
Carcinogenesis; 2007 Jun; 28(6):1259-63. PubMed ID: 17277229
[TBL] [Abstract][Full Text] [Related]
3. A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma.
Edwards TL; Shrubsole MJ; Cai Q; Li G; Dai Q; Rex DK; Ulbright TM; Fu Z; Murff HJ; Smalley W; Ness R; Zheng W
Cancer Prev Res (Phila); 2012 Jun; 5(6):855-63. PubMed ID: 22551900
[TBL] [Abstract][Full Text] [Related]
4. LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs.
Al-Kharusi MR; Smartt HJ; Greenhough A; Collard TJ; Emery ED; Williams AC; Paraskeva C
Carcinogenesis; 2013 May; 34(5):1150-7. PubMed ID: 23349017
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Potter JD; Ulrich CM
Pharmacogenet Genomics; 2009 Feb; 19(2):113-20. PubMed ID: 19077918
[TBL] [Abstract][Full Text] [Related]
6. XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk.
Stern MC; Siegmund KD; Corral R; Haile RW
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):609-15. PubMed ID: 15767338
[TBL] [Abstract][Full Text] [Related]
7. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption.
Siezen CL; van Leeuwen AI; Kram NR; Luken ME; van Kranen HJ; Kampman E
Carcinogenesis; 2005 Feb; 26(2):449-57. PubMed ID: 15550453
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.
Kleinstein SE; Heath L; Makar KW; Poole EM; Seufert BL; Slattery ML; Xiao L; Duggan DJ; Hsu L; Curtin K; Koepl L; Muehling J; Taverna D; Caan BJ; Carlson CS; Potter JD; Ulrich CM
Genes Chromosomes Cancer; 2013 May; 52(5):437-49. PubMed ID: 23404351
[TBL] [Abstract][Full Text] [Related]
9. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.
Ulrich CM; Whitton J; Yu JH; Sibert J; Sparks R; Potter JD; Bigler J
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):616-9. PubMed ID: 15767339
[TBL] [Abstract][Full Text] [Related]
10. Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development.
Pereira C; Queirós S; Galaghar A; Sousa H; Pimentel-Nunes P; Brandão C; Moreira-Dias L; Medeiros R; Dinis-Ribeiro M
PLoS One; 2014; 9(4):e92000. PubMed ID: 24694755
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta.
Siezen CL; Tijhuis MJ; Kram NR; van Soest EM; de Jong DJ; Fodde R; van Kranen HJ; Kampman E
Pharmacogenet Genomics; 2006 Jan; 16(1):43-50. PubMed ID: 16344721
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry.
Resler AJ; Makar KW; Heath L; Whitton J; Potter JD; Poole EM; Habermann N; Scherer D; Duggan D; Wang H; Lindor NM; Passarelli MN; Baron JA; Newcomb PA; Le Marchand L; Ulrich CM
Carcinogenesis; 2014 Sep; 35(9):2121-6. PubMed ID: 24908683
[TBL] [Abstract][Full Text] [Related]
13. Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance.
Guda K; Fink SP; Milne GL; Molyneaux N; Ravi L; Lewis SM; Dannenberg AJ; Montgomery CG; Zhang S; Willis J; Wiesner GL; Markowitz SD
Cancer Prev Res (Phila); 2014 Aug; 7(8):805-12. PubMed ID: 24838973
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma.
Gong Z; Bostick RM; Xie D; Hurley TG; Deng Z; Dixon DA; Zhang J; Hebert JR
Int J Colorectal Dis; 2009 Jun; 24(6):647-54. PubMed ID: 19205707
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial.
Sansbury LB; Bergen AW; Wanke KL; Yu B; Caporaso NE; Chatterjee N; Ratnasinghe L; Schatzkin A; Lehman TA; Kalidindi A; Modali R; Lanza E
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):494-501. PubMed ID: 16537707
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk.
Davenport JR; Cai Q; Ness RM; Milne G; Zhao Z; Smalley WE; Zheng W; Shrubsole MJ
Mol Carcinog; 2016 Aug; 55(8):1251-61. PubMed ID: 26333108
[TBL] [Abstract][Full Text] [Related]
17. Variation in folate pathway genes and distal colorectal adenoma risk: a sigmoidoscopy-based case-control study.
Levine AJ; Lee W; Figueiredo JC; Conti DV; Vandenberg DJ; Davis BD; Edlund CK; Henning SM; Heber D; Stern MC; Haile RW
Cancer Causes Control; 2011 Apr; 22(4):541-52. PubMed ID: 21274745
[TBL] [Abstract][Full Text] [Related]
18. Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Daugherty SE; Platz EA; Shugart YY; Fallin MD; Isaacs WB; Chatterjee N; Welch R; Huang WY; Hayes RB
Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1536-42. PubMed ID: 17684125
[TBL] [Abstract][Full Text] [Related]
19. Genetic variability in IL23R and risk of colorectal adenoma and colorectal cancer.
Poole EM; Curtin K; Hsu L; Duggan DJ; Makar KW; Xiao L; Carlson CS; Caan BJ; Potter JD; Slattery ML; Ulrich CM
Cancer Epidemiol; 2012 Apr; 36(2):e104-10. PubMed ID: 22154103
[TBL] [Abstract][Full Text] [Related]
20. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence.
Chell SD; Witherden IR; Dobson RR; Moorghen M; Herman AA; Qualtrough D; Williams AC; Paraskeva C
Cancer Res; 2006 Mar; 66(6):3106-13. PubMed ID: 16540660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
